Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BROMOCRIPTINE MESYLATE vs CYCLOSET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
FDA-approved: Treatment of hyperprolactinemia (including amenorrhea/galactorrhea, hypogonadism, infertility) associated with prolactin-secreting adenomas,FDA-approved: Adjunctive treatment of Parkinson disease (idiopathic or postencephalitic),FDA-approved: Treatment of acromegaly (as an adjunct to surgery or radiotherapy),Off-label: Type 2 diabetes mellitus (improves glycemic control),Off-label: Neuroleptic malignant syndrome,Off-label: Prevention of postpartum lactation (use not recommended due to serious adverse events)
FDA-approved: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,Off-label: Parkinson's disease, hyperprolactinemia, acromegaly, neuroleptic malignant syndrome.
Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged to 12-14 hours in patients with hepatic impairment or in the elderly.
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
Extensively metabolized primarily by cytochrome P450 3A4 (CYP3A4) to multiple metabolites, including the major active metabolite 2-bromo-α-ergocriptine. Also undergoes non-CYP-mediated hydrolysis and conjugation. First-pass metabolism is significant, resulting in ~6% oral bioavailability.
Primarily hepatic via cytochrome P450 3A4 (CYP3A4). Inactive metabolites are excreted mainly in feces (80%) and urine (2-10% unchanged).
Primarily hepatic metabolism with 85-90% fecal excretion via bile; <5% renal excretion as unchanged drug and metabolites.
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
90-96% bound to serum albumin, with some binding to alpha-1-acid glycoprotein.
~20–30% bound, primarily to albumin.
Approximately 2-3 L/kg, indicating extensive tissue distribution and penetration into breast milk and central nervous system.
0.5–1.0 L/kg, indicating moderate distribution into tissues.
Oral: 28-30% due to extensive first-pass metabolism; sublingual: 40-50% due to partial avoidance of hepatic first-pass; rectal: approximately 20%.
Oral: ~65–75% due to first-pass metabolism.
No specific dose adjustment recommended; monitor for accumulation in severe renal impairment (e GFR <30 m L/min).
Contraindicated in patients with e GFR <30 m L/min/1.73 m2. For e GFR 30-50 m L/min/1.73 m2: maximum dose 0.8 mg daily.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Avoid use.
No dose adjustment required for mild hepatic impairment (Child-Pugh class A). Not recommended in moderate to severe hepatic impairment (Child-Pugh class B or C) due to lack of data.
Prolactinomas: 1.25-2.5 mg/m²/day orally in 2-3 divided doses; titrate based on response. Weight-based: 0.01-0.02 mg/kg/day, increase slowly.
Not approved for pediatric patients. Safety and efficacy in patients <18 years have not been established.
Initiate at low end of dosing range (1.25 mg once or twice daily) due to increased sensitivity and risk of hypotension; titrate slowly.
Start at 0.8 mg once daily; titrate slowly due to increased risk of orthostatic hypotension and hypoglycemia. Consider renal function and comorbidities.
None
None.
May cause hypotension (especially postural), syncope, and severe adverse reactions such as myocardial infarction, stroke, seizures, and psychosis. Can cause pleural and retroperitoneal fibrosis, pericarditis, and valvulopathy (especially with high doses for Parkinson disease). Has been associated with pathological gambling, hypersexuality, and impulse control disorders. May cause somnolence and sudden sleep onset. Monitor for cardiac valvulopathy and pulmonary fibrosis. Use with caution in patients with cardiovascular disease, peptic ulcer disease, or a history of mental illness.
Risk of hypotension, especially at initiation of therapy; monitor blood pressure.,May cause somnolence and dizziness; advise patients not to drive or operate machinery until effects are known.,Use with caution in patients with cardiovascular disease, especially those with angina or recent myocardial infarction.,May exacerbate psychotic disorders; use caution in patients with a history of psychosis.,Fibrotic complications (pulmonary, pericardial, retroperitoneal fibrosis) have been reported with ergot-derived dopamine agonists; monitor for symptoms.,Discontinue if signs of cardiac valvulopathy occur.
Absolute: Hypersensitivity to bromocriptine or ergot alkaloids; uncontrolled hypertension; pregnancy (toxemia of pregnancy); preeclampsia/eclampsia; coronary artery disease or other significant cardiovascular disease; severe renal or hepatic impairment. Relative: History of peptic ulcer disease, psychiatric disorders, Raynaud phenomenon, or hepatic impairment.
Hypersensitivity to bromocriptine or any component of the formulation.,Concomitant use with CYP3A4 inducers (e.g., rifampin, anticonvulsants) or inhibitors (e.g., azole antifungals, macrolide antibiotics).,Severe ischemic heart disease or peripheral vascular disorders.,Syncopal migraine or history of myocardial infarction with residual arrhythmias.,Uncontrolled hypertension.,Lactation: inhibits lactation, do not use in women with pregnancy or nursing unless essential.
Take with food to reduce gastrointestinal irritation; avoid high-protein meals if using for hyperprolactinemia as protein may decrease absorption.
Avoid alcohol and alcohol-containing products. No specific food interactions; take with or without food. Maintain adequate hydration.
First trimester: Limited human data; animal studies show increased fetal resorption and growth retardation at high doses. Second and third trimesters: Risk of postpartum hemorrhage due to uterine atony; may suppress pituitary prolactin, potentially impairing placental lactogen production. Overall, use only if clearly needed.
First trimester: insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: no known fetal risks; drug may cause maternal hypoglycemia which can affect fetus.
Bromocriptine suppresses lactation by inhibiting prolactin secretion. It is contraindicated in breastfeeding women due to the intended suppression of milk production. No M/P ratio available; minimal excretion into breast milk is expected but not well studied.
Not recommended; no data on excretion in human milk. M/P ratio unknown.
No specific dose adjustments are recommended for pregnancy; however, the drug is generally discontinued once pregnancy is confirmed unless necessary for prolactinoma treatment. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may theoretically alter levels, but data are insufficient to recommend dose changes.
Monitor glucose closely; dose adjustments may be needed due to altered pharmacokinetics in pregnancy (increased clearance). Start at lowest effective dose; titrate based on glycemic response.
Titrate slowly to minimize orthostatic hypotension and gastrointestinal upset. Administer with food to reduce nausea. Monitor for pulmonary fibrosis and Raynaud phenomenon with long-term use. Avoid concomitant use with ergot alkaloids due to additive vasospasm risk.
Monitor for hypoglycemia, especially in elderly patients or those with renal impairment. Cycloserine may accumulate in renal insufficiency; dose reduction is necessary if Cr Cl < 50 m L/min. Watch for neuropsychiatric effects (seizures, psychosis, depression) and discontinue if severe. Pyridoxine 50-100 mg daily is recommended to reduce neurotoxicity. Avoid alcohol due to increased seizure risk.
Take with food to reduce nausea and lightheadedness.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol as it may worsen side effects.,Report persistent cough, chest pain, or changes in urination or vision.,Do not stop abruptly; taper under medical supervision.
Take exactly as prescribed; do not miss doses or double up.,Report any signs of rash, confusion, dizziness, or unusual behavior immediately.,Avoid alcohol completely while on this medication.,If you have kidney problems, your dose may need adjustment.,Take pyridoxine (vitamin B6) as directed to lower risk of side effects.,Do not drive or operate heavy machinery if you feel drowsy or dizzy.,Complete the full course of therapy even if you feel better.
"Coadministration of bromocriptine, a dopamine D2 receptor agonist with vasoconstrictive properties, and ergometrine, an ergot alkaloid that acts as a partial agonist at alpha-adrenergic and serotonin receptors, synergistically increases peripheral vasoconstriction. This additive effect can lead to severe hypertension, myocardial ischemia, cerebral vasospasm, and potentially life-threatening ergotism. Patients may present with headache, chest pain, altered mental status, or peripheral ischemia."
"Concurrent use of bromocriptine, a dopamine D2 receptor agonist, and enasidenib, an IDH2 inhibitor, may lead to increased risk of central nervous system adverse effects, including dizziness, somnolence, and extrapyramidal symptoms. Enasidenib inhibits CYP3A4, which metabolizes bromocriptine, potentially elevating bromocriptine plasma concentrations. This pharmacokinetic interaction can exacerbate dopaminergic toxicity, especially in patients with hepatic impairment or those on high-dose bromocriptine."
"Bromocriptine, a dopamine D2 receptor agonist and ergot derivative, is primarily metabolized by CYP3A4. Astemizole, a second-generation antihistamine, is also metabolized by CYP3A4. Concomitant use of these two drugs can lead to competitive inhibition of CYP3A4, resulting in increased plasma concentrations of both agents. Elevated bromocriptine levels raise the risk of ergotism (vasospasm, ischemia) and neuropsychiatric toxicities, while increased astemizole concentrations may prolong the QT interval, predisposing patients to life-threatening ventricular arrhythmias such as torsades de pointes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BROMOCRIPTINE MESYLATE vs CYCLOSET, answered by our medical review team.
BROMOCRIPTINE MESYLATE is a Dopamine Agonist that works by Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.. CYCLOSET is a Dopamine Agonist / Antidiabetic that works by Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BROMOCRIPTINE MESYLATE and CYCLOSET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BROMOCRIPTINE MESYLATE is: Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).. The standard adult dose of CYCLOSET is: 1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BROMOCRIPTINE MESYLATE and CYCLOSET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BROMOCRIPTINE MESYLATE is classified as Category A/B. First trimester: Limited human data; animal studies show increased fetal resorption and growth retardation at high doses. Second and third trimesters: Risk of postpartum hemorrhage. CYCLOSET is classified as Category C. First trimester: insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: no known fetal risks; drug may cause mate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.